Search results for "inactive"

showing 3 items of 13 documents

Mediterranean diet impact on cardiovascular diseases: a narrative review

2017

Cardiovascular disease (CVD) accounts for more than 17 million deaths per year worldwide. It has been estimated that the influence of lifestyle on CVD mortality amounts to 13.7% for smoking, 13.2% for poor diet, and 12% for inactive lifestyle. These results deeply impact both the healthy status of individuals and their skills in working. The impact of CVD on productivity loss accounts for the 24% in total costs for CVD management. Mediterranean diet (MedD) can positively impact on natural history of CVD. It is characterized by a relatively high consumption of inexpensive and genuine food such as cereals, vegetables, legumes, nuts, fish, fresh fruits, and olive oil as the principal source of…

lifestyleMediterranean dietinactive lifestyleDisease030204 cardiovascular system & hematologyDiet MediterraneanSudden cardiac deathCoronary artery disease03 medical and health sciencescardiovascular diseases lifestyle Mediterranean diet preventive cardiology vascular diseasesVascular Stiffness0302 clinical medicinecardiovascular diseaseEnvironmental healthMediterranean dietmedicineHumansHealthy Lifestyle030212 general & internal medicineMediterranean diet impact on cardiovascular diseasesRandomized Controlled Trials as TopicalimentationTraditional medicinebusiness.industrycardiovascular disease (CVD)preventive cardiologyfood and beveragesvascular diseasemediterranean dietGeneral Medicinemedicine.diseaseNatural historycardiovascular diseases; lifestyle; Mediterranean diet; preventive cardiology; vascular diseases; Cardiology and Cardiovascular MedicineCardiovascular Diseasesmediterranean diet cardiovascular diseaseHeart failureArterial stiffnesscardiovascular disease (CVD); inactive lifestyle; alimentationvascular diseasesNarrative reviewbusinessCardiology and Cardiovascular Medicine
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

Sezernierter Interleukin-2-Rezeptor als Aktivitätsparameter der Sarkoidose*

2008

Serum sIL-2-R levels were measured in 28 sarcoidosis patients at multiple time points before, during, and after therapy, with a mean follow-up time of 10.2 +/- 5.2 months, and the results compared with the clinical activity of the disease. Before therapy, 20 out of 24 episodes with active disease exhibited elevated levels of sIL-2-R (918 +/- 362 U/ml). In inactive disease after tapering off corticoid therapy the sIL-2-R levels were 453 +/- 274 U/ml. Disease activity under therapy also correlated with sIL-2-R serum levels. 23 out of 29 episodes with signs of activity under therapy had elevated sIL-2-R levels (808 +/- 409 U/ml). Only three of 28 patients in whom disease activity ceased after …

medicine.medical_specialtybusiness.industryGeneral MedicineDiseasemedicine.diseaseGastroenterologyfemale genital diseases and pregnancy complicationsDisease activityPulmonary sarcoidosisimmune system diseaseshemic and lymphatic diseasesInternal medicineActive diseaseMultiple timeMedicineSarcoidosisbusinessInactive diseaseReceptorDMW - Deutsche Medizinische Wochenschrift
researchProduct